BioSpace News Archive

The current standard-of-care for millions of patients across the world with diabetic macular edema (DME) relies on invasive injections or implants into the eye, both of which are associated with serious risks and side effects

Kopin Corporation, a leading developer of innovative wearable computing technologies and solutions, announced today that it has entered into an agreement to support the development and commercialization of the next generation of head mounted displays (HMD) designed for advanced medical and surgical applications.

Today, we took an important step forward in combatting the devastating crisis of opioid addiction plaguing our nation.

ICON plc (NASDAQ: ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the third quarter ended September 30, 2018.

Health Canada is advising Canadians that the following products may pose serious health risks. For more information, including what Canadians should do, visit the online safety alert.

Eyevance Pharmaceuticals, a Fort Worth-based pharmaceutical company committed to developing and commercializing innovative and impactful ophthalmic products, today announced the acquisition of FLAREX®

Clinical Support Services has created a new, value-based adherence program for health plans designed to raise the proportion of days covered (PDC) for fragile populations with multiple co-morbidities to at least 80%.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Food and Drug Administration (FDA) has approved XOFLUZA™ (baloxavir marboxil) for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of age and older.

Illinois American Water encourages customers to participate in the Drug Enforcement Agency’s (DEA) National Prescription Drug Take Back Day. Residents are encouraged to drop off their unwanted medications at approved collection sites so they can be incinerated, which is the Environmental Protection Agency’s (EPA) recommended approach for pharmaceutical disposal.

NX Prenatal, a privately held women’s healthcare molecular diagnostic company, announced today that it has entered into a collaboration with Indiana University School of Medicine to further validate its early pregnancy biomarker panels that predict Spontaneous Preterm Birth (SPTB) and to further develop its biomarker panels for Preeclampsia (PE).